KROS – keros therapeutics, inc. - common stock (US:NASDAQ)

News

Keros Therapeutics, Inc. (NASDAQ: KROS) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $84.00 price target on the stock.
Keros Therapeutics, Inc. (NASDAQ: KROS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $100.00 price target on the stock.
Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results [Yahoo! Finance]
Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results
Keros Therapeutics to Present at the Guggenheim Healthcare Innovation Conference
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com